Gu, Wei

Acetylation targeting chimera enables acetylation of the tumor suppressor p53

Kabir, M., Sun, N., Hu, X., Martin, T. C., Yi, J., Zhong, Y., Xiong, Y., Kaniskan, H. Ü., Gu, W., Parsons, R., et al. (2023) · Journal of the American Chemical Society

Protein Degradation and InhibitorsChemical Synthesis and Analysis

Cited by 65

Deciphering the acetylation code of p53 in transcription regulation and tumor suppression

Xia, Z., Kon, N., Gu, A. P., Tavana, O., & Gu, W. (2022) · Oncogene

Cancer-related Molecular PathwaysGenomics and Chromatin Dynamics

Cited by 60

USP7 enforces heterochromatinization of p53 target promoters by protecting SUV39H1 from MDM2-mediated degradation.

Mungamuri, S. K., Qiao, R. F., Yao, S., Manfredi, J. J., Gu, W., & Aaronson, S. A. (2016) · Cell Reports

Ubiquitin and proteasome pathwaysCancer-related Molecular Pathways

Cited by 54

p53-mediated heterochromatin reorganization regulates its cell fate decisions.

Mungamuri, S. K., Benson, E. K., Wang, S., Gu, W., Lee, S. W., & Aaronson, S. A. (2012) · Nature Structural & Molecular Biology

Cancer-related Molecular PathwaysGenomics and Chromatin Dynamics

Cited by 53

SIRT7 activates p53 by enhancing PCAF-mediated MDM2 degradation to arrest the cell cycle

Lu, Y.-F., Xu, X.-P., Lu, X.-P., Zhu, Q., Liu, G., Bao, Y.-T., Wen, H., Li, Y.-L., Gu, W., & Zhu, W.-G. (2020) · Oncogene

Sirtuins and Resveratrol in MedicineCancer-related Molecular Pathways

Cited by 40

Design, synthesis, and evaluation of p53Y220C acetylation targeting chimeras (AceTACs)

Hu, X., Kabir, M., Lin, Y., Xiong, Y., Parsons, R. E., Gu, W., & Jin, J. (2024) · Journal of Medicinal Chemistry

Cancer-related Molecular PathwaysProtein Degradation and Inhibitors

Cited by 9